Stocks and Investing Stocks and Investing
Mon, March 4, 2019
Fri, March 1, 2019

Joel Beatty Maintained (SRPT) at Strong Buy with Increased Target to $201 on, Mar 1st, 2019


Published on 2024-10-26 12:24:03 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $188 to $201 on, Mar 1st, 2019.

Joel has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Joel's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Joel


  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $231 on, Thursday, February 28th, 2019
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $230 on, Thursday, February 28th, 2019

Contributing Sources